Immunovant (IMVT) Retained Earnings (2018 - 2026)
Immunovant's (IMVT) quarterly Retained Earnings came in at -$1.7 billion in Q1 2026, down 119709.32% YoY from N/an in Q1 2025, and down 9.25% on a QoQ basis from -$1.6 billion in Q4 2025.
Immunovant (IMVT) Retained Earnings (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Retained Earnings data on file, last reported at -$1.7 billion in Q1 2026.
- Quarterly Retained Earnings fell 119709.32% year-over-year to -$1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 119709.32% YoY) and the FY2026 annual result came in at -$1.7 billion, down 119709.32% from the prior year.
- Retained Earnings retreated to -$1.7 billion in Q1 2026, from -$1.6 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $2.0 billion in Q3 2025 to a low of -$1.7 billion in Q1 2026.
- A 5-year average of -$315.5 million and a median of -$355.4 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings surged 357344.87% — and 2024, when it sank 199310.92%.
- Tracing IMVT's Retained Earnings over 5 years: stood at $920.2 million in 2022, then tumbled by 181.54% to -$750.4 million in 2023, then plunged by 51.0% to -$1.1 billion in 2024, then sank by 40.97% to -$1.6 billion in 2025, then declined by 9.25% to -$1.7 billion in 2026.
- The last three Retained Earnings figures came in at -$1.7 billion (Q1 2026), -$1.6 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 2.63 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.63 Bn |
| Mar 31, 2026 | -1.75 Bn |
| Dec 31, 2025 | -1.60 Bn |
| Sep 30, 2025 | 2.00 Bn |
| Jun 30, 2025 | -1.36 Bn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | -1.13 Bn |
| Sep 30, 2024 | -1.02 Bn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | -825.68 Mn |
| Dec 31, 2023 | -750.36 Mn |
| Sep 30, 2023 | 513,000.00 |
| Jun 30, 2023 | 939.55 Mn |
| Mar 31, 2023 | 852,000.00 |
| Dec 31, 2022 | 920.20 Mn |
| Sep 30, 2022 | -443.70 Mn |
| Jun 30, 2022 | -263,000.00 |
| Mar 31, 2022 | -355.39 Mn |
| Dec 31, 2021 | -308.20 Mn |
| Sep 30, 2021 | -266.83 Mn |